Chinese radiopharmaceutical startup C Ray Therapeutics announced on Saturday that it has raised over $100 million in a Series A+ funding round to strengthen its technology platform and expedite the clinical development of pipeline drugs.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
